{"id":1146,"date":"2023-12-22T04:55:56","date_gmt":"2023-12-22T04:55:56","guid":{"rendered":"https:\/\/o-force.info\/?page_id=1146"},"modified":"2025-02-21T02:04:14","modified_gmt":"2025-02-21T02:04:14","slug":"research-progress","status":"publish","type":"page","link":"https:\/\/o-force.info\/index.php\/en\/catalytide-research-lab\/research-progress\/","title":{"rendered":"Research Progress"},"content":{"rendered":"\n

Fiscal Year 2020<\/strong><\/p>\n\n\n\n

Funding started by AMED Bridging Research Grant, Seeds A<\/p>\n\n\n\n

Reserach on aggregation of 6 kinds of fragment peptides derived from amyloid-\u03b2<\/p>\n\n\n\n

Screening of 150 synthetic peptides for their aggregation inhibitory effects<\/p>\n\n\n\n

Patent application (Kochi University): Japan<\/p>\n\n\n\n

Aggregation inhibition and aggregation disengagement peptide<\/p>\n\n\n\n

Patent Application 2020-167404 \"Amyloid-\u03b2 aggregation inhibitor, pharmaceutical composition for amyloid-\u03b2 aggregation disease, and uses thereof\u201d<\/p>\n\n\n\n

Reinforcing patent pending<\/p>\n\n\n\n

No effect on \u03b1-synuclein (Parkinson's disease) or SOD1 (ALS), and specific for A\u03b225-35 (Alzheimer's disease)<\/p>\n\n\n\n

Verification of pharmacological effects<\/p>\n\n\n\n

Cognitive function assessment methods (Y-maze test, open field test, object recognition test, social-behavioral analysis)<\/p>\n\n\n\n

Identification of peptides that improve cognitive function in a mouse model of A\u03b225-35 intrahippocampal administration<\/p>\n\n\n\n

Evaluation of motor function (Rotor Rod)<\/p>\n\n\n\n

Identification of peptides that improve motor function in a mouse model of Syn61-84 intracerebroventricular administration<\/p>\n\n\n\n

Fiscal Year 2021<\/strong><\/p>\n\n\n\n

Funding continues by AMED Bridging Research Grant, Seeds A<\/p>\n\n\n\n

Started screening for ALS and Tau<\/p>\n\n\n\n

Patent application (Kochi University): Japan<\/p>\n\n\n\n

Aggregation inhibitor, aggregation disengagement peptide<\/p>\n\n\n\n

Patent Application 2021-08513 \"Amyloid-\u03b2 aggregation inhibitor, pharmaceutical composition for amyloid-\u03b2 aggregation disease, and uses thereof\"<\/p>\n\n\n\n

Patent  Application 2021-08512 \"Aggregation inhibitor of \u03b1-synuclein, pharmaceutical compositions for \u03b1-synuclein aggregation diseases, and uses thereof\"<\/p>\n\n\n\n

Determining dosage and route of administration (research on effects in intranasal administration)<\/p>\n\n\n\n

Safety (research on acute toxicity, chronic toxicity, and lethal dose)<\/p>\n\n\n\n

Collaboration with companies<\/p>\n\n\n\n

BioJapan (booth & matching)<\/p>\n\n\n\n

Joint research with domestic companies and a domestic pharmaceutical company<\/p>\n\n\n\n

Fiscal Year 2022<\/strong><\/p>\n\n\n\n

Started joint research with a domestic pharmaceutical company and Kochi University for clinical trials.<\/p>\n\n\n\n

Fiscal Year 2023<\/strong><\/p>\n\n\n\n

Intranasal administration of our peptides to Alzheimer's disease model mice improved cognitive function.<\/p>\n\n\n\n

Intranasal administration of peptides to Parkinson's disease model mice suppressed mobility dysfunction.<\/p>\n\n\n\n

Fiscal Year 202<\/strong>4<\/h2>\n\n\n\n

Alzheimer's disease: Peptide (JAL-TA9) degraded amyloid-beta in the human brain slices. Using monkeys, the concentration of JAL-TA9 in cerebrospinal fluid was measured, and its distribution was evaluated.<\/p>\n\n\n\n

Parkinson's disease: Evaluation of peptide (PD-Cat) effect on pathological hallmarks of Parkinson's disease in human patient brain slices using immunohistochemical analysis.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Fiscal Year 2020 Funding started by AMED Bridging Research Grant, Seeds A Reserach on aggregation of 6 kinds o […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1144,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"sns_share_botton_hide":"","vkExUnit_sns_title":"","_vk_print_noindex":"","sitemap_hide":"","vkExUnit_sitemap":"","_veu_custom_css":"","veu_display_promotion_alert":"common","_exclude_from_list_pages":"","vkexunit_cta_each_option":"","vkExUnit_childPageIndex":"","vkExUnit_pageList_ancestor":"","vkExUnit_contact_enable":"","footnotes":""},"class_list":["post-1146","page","type-page","status-publish","hentry"],"aioseo_notices":[],"veu_head_title_object":{"title":"","add_site_title":""},"_links":{"self":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/pages\/1146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/comments?post=1146"}],"version-history":[{"count":8,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/pages\/1146\/revisions"}],"predecessor-version":[{"id":2091,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/pages\/1146\/revisions\/2091"}],"up":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/pages\/1144"}],"wp:attachment":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/media?parent=1146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}